Millions Worldwide Lack Access to Essential Parkinson’s Disease Medication

Despite being a proven and inexpensive treatment for over half a century, the vital medication levodopa is becoming increasingly unavailable to the 11.8 million people globally living with Parkinson’s disease, raising concerns about a growing public health crisis.

Levodopa, a dopamine-replacement pill, dramatically improved the lives of Parkinson’s patients after its discovery in the late 1960s, restoring mobility and independence. However, access remains unevenly distributed, particularly in low- and middle-income countries where supply chains are unreliable and costs can be prohibitive. This lack of access forces many patients to choose between essential medication and basic necessities like food. The situation is particularly alarming given the projected doubling of Parkinson’s cases in the next 25 years.

Experts point to the success of the global response to the HIV/AIDS epidemic as a model for addressing this challenge. International coordination, policy changes, and sustained advocacy made antiretroviral drugs available worldwide, transforming a death sentence into a manageable condition for over 29 million people. “The global HIV response showed what’s possible when science, policy, and activism align,” highlighting the potential for similar success with Parkinson’s disease. Addressing this issue is critical as Parkinson’s is now the fastest-growing neurodegenerative disease globally. Further research into potential treatments, such as stem cell therapies, offers hope, but current treatment gaps must be addressed immediately.

To improve access, advocates are calling for levodopa to be added to every country’s essential medicines list, bulk procurement at negotiated prices, strengthened distribution systems, and rigorous quality control to combat counterfeit drugs. Officials have stated the need for transparent data on access and accountability to ensure targets are met, mirroring the strategies employed during the HIV/AIDS crisis. The National Institute of Neurological Disorders and Stroke provides comprehensive information on Parkinson’s disease and ongoing research.

Leaders are expected to discuss strategies for a coordinated global response to Parkinson’s disease at an upcoming international health summit, with a focus on establishing a multinational funding mechanism and a U.N. target for levodopa access.